跳至主要内容
临床试验/NCT00959569
NCT00959569已完成4 期

Esmolol in Cardiac Surgery. A Randomized Controlled Trial With Clinical

Università Vita-Salute San Raffaele1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
200
试验地点
1
主要终点
Composite endpoint of number of dead patients and/or number of patients requiring prolonged ICU stay.

研究概览

简要总结

This large randomized double-blind clinical trial (esmolol vs placebo) will enroll patients undergoing cardiac surgery to study the additive cardiac protection of this therapeutic strategy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • end diastolic diameter >60 mm and/or an ejection fraction <50%
  • written informed consent
  • age >18 years

排除标准

  • previous unusual response to esmolol
  • inclusion in other randomized studies
  • esmolol administration in the previous 30 days
  • emergency operation

研究组 & 干预措施

esmolol

Experimental

the study group will receive esmolol (1-3 mg/kg)

干预措施: Esmolol (Drug)

normosaline

Placebo Comparator

normosaline (same ml of the study drug)

干预措施: Placebo (Drug)

结局指标

主要结局

Composite endpoint of number of dead patients and/or number of patients requiring prolonged ICU stay.

时间窗: Hospital stay (approximately 2 weeks)

次要结局

  • Number of patients with ventricular fibrillation after cardiopulmonary bypass(30 days and 1 year)
  • Number of patients with low cardiac output syndrome(30 days and 1 year)
  • peak postoperative cardiac troponin level(30 days and 1 year)
  • Number of patients requiring post-operative inotropic support(30 days and 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Giovanni Landoni

MD

Università Vita-Salute San Raffaele

研究点 (1)

Loading locations...

相似试验